BioNTech SE stock (US09075V1026): ASCO lung cancer data with Bristol Myers Squibb puts oncology pipeline in focus

BioNTech SE, listed on Nasdaq under the ticker BNTX and headquartered in Germany, is back in the spotlight after the company and its U.S. partner Bristol Myers Squibb reported encouraging interim Phase 2 results from the ROSETTA Lung-02 trial in advanced non-small cell lung cancer, a development that aligns with presentations around the ASCO 2026 oncology conference and underscores the importance of the United States as BioNTech's primary equity market and regulatory arena for this program, according to BioNTech investor relations as of 05/31/2026 and Gurufocus as of 05/31/2026.

On the last trading day before publication, BNTX closed on Nasdaq in the United States with moderate gains while German investors saw the stock at EUR 82.35 in Xetra trading on 05/29/2026, up 2.68 percent on the day and 3.20 percent for the week, showing how the ASCO-related news is resonating both in the home U.S. listing and in the secondary German market, according to Aktiencheck as of 05/31/2026.

The new ROSETTA Lung-02 data concern pumitamig, described as the first PD-(L)1xVEGF bispecific immunomodulator to show positive efficacy data together with chemotherapy in the first-line treatment of advanced non-small cell lung cancer, where interim results at the lower dose level showed confirmed objective response rates of 63.6 percent in the non-squamous subgroup and 72.7 percent in the squamous subgroup, according to Gurufocus as of 05/31/2026.

For U.S.-based investors following the Nasdaq listing, this lung cancer program adds a second pillar to BioNTech shares beyond the COVID-19 vaccine, with the immuno-oncology pipeline now featuring a late-stage candidate co-developed with Bristol Myers Squibb that could, if confirmed in Phase 3, complement or expand on existing checkpoint inhibitor standards in the U.S. market.

In Germany, the stock is also accessible for retail investors via venues such as Xetra and Tradegate, where the recent move to around EUR 82 on 05/31/2026, compared with a 52-week high of EUR 111 and a 52-week low of EUR 68.35, illustrates how the pipeline news is being priced relative to past volatility, according to the same Xetra-based data cited by Aktiencheck as of 05/31/2026.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

BioNTech SE: core business model

BioNTech SE focuses on developing and commercializing mRNA-based vaccines and immune-based cancer therapies, with revenue primarily generated through its COVID-19 vaccine collaboration and milestone and royalty streams from a growing late-stage oncology pipeline.

What banks and research houses say about BioNTech SE

For the Monday module, the lens shifts to analyst coverage, where international investment banks track BioNTech in the context of both its COVID-19 cash flows and its emerging oncology assets, including the ROSETTA Lung-02 bispecific immunomodulator pumitamig with Bristol Myers Squibb. While details of individual analyst target prices can vary, the general framing in recent research is that the ASCO 2026 data contribute to the credibility of BioNTech's goal of achieving its first oncology product approval in the next few years, adding another dimension to models that currently lean heavily on U.S. and European COVID-19 vaccine sales.

Commentary gathered around the ASCO period indicates that banks are now updating their models to incorporate the probability of success and potential market size in advanced non-small cell lung cancer, an indication that is one of the largest oncology markets in the United States, and these updates are largely focused on how the ROSETTA Lung-02 program might complement or compete with existing PD-1 and PD-L1 inhibitors, with the U.S. Food and Drug Administration pathway likely to be central to how earnings and valuation multiples are reassessed in coming quarters.

Conclusion

The latest interim Phase 2 ROSETTA Lung-02 results presented around ASCO 2026 give BioNTech a tangible late-stage oncology asset alongside its COVID-19 vaccine business, and the positive pumitamig response rates in both non-squamous and squamous advanced non-small cell lung cancer cohorts provide an additional clinical proof point in a key United States oncology market. For equity investors on Nasdaq and on German venues like Xetra, the focus now moves to how U.S. and European regulators respond to the accumulating data and how banks and research houses recalibrate their earnings and valuation models as BioNTech seeks to transition from a pandemic-driven revenue profile to a more diversified oncology-led portfolio. In this context, the interplay between trial readouts, regulatory milestones and analyst assumptions is likely to shape trading ranges for BNTX stock across both its U.S. home exchange and its secondary European listings over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.